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BRCA2-mutated breast cancers predict benefit of
intensified carboplatin-based chemotherapy
Marieke A Vollebergh1,6†, Esther H Lips1,3†, Petra M Nederlof3, Lodewyk FA Wessels2,7, Jelle Wesseling3,
Marc J vd Vijver8, Elisabeth GE de Vries9, Harm van Tinteren4, Jos Jonkers1, Michael Hauptmann5,
Sjoerd Rodenhuis6 and Sabine C Linn1,6,10*Abstract
Introduction: BRCA-mutated breast cancer cells lack the DNA-repair mechanism homologous recombination that is
required for error-free DNA double-strand break (DSB) repair. Homologous recombination deficiency (HRD) may
cause hypersensitivity to DNA DSB-inducing agents, such as bifunctional alkylating agents and platinum salts. HRD
can be caused by BRCA mutations, and by other mechanisms. To identify HRD, studies have focused on triple-negative
(TN) breast cancers as these resemble BRCA1-mutated breast cancer closely and might also share this hypersensitivity.
However, ways to identify HRD in non-BRCA-mutated, estrogen receptor (ER)-positive breast cancers have remained
elusive. The current study provides evidence that genomic patterns resembling BRCA1- or BRCA2-mutated breast
cancers can identify breast cancer patients with TN as well as ER-positive, HER2-negative tumors that are sensitive to
intensified, DSB-inducing chemotherapy.
Methods: Array comparative genomic hybridization (aCGH) was used to classify breast cancers. Patients with tumors
with similar aCGH patterns as BRCA1- and/or BRCA2-mutated breast cancers were defined as having a BRCA-likeCGH
status, others as non-BCRA-likeCGH. Stage-III patients (n = 249) had participated in a randomized controlled trial of adjuvant
high-dose (HD) cyclophosphamide-thiotepa-carboplatin (CTC) versus 5-fluorouracil-epirubicin-cyclophosphamide
(FE90C) chemotherapy.
Results: Among patients with BRCA-likeCGH tumors (81/249, 32%), a significant benefit of HD-CTC compared to
FE90C was observed regarding overall survival (adjusted hazard ratio 0.19, 95% CI: 0.08 to 0.48) that was not seen
for patients with non-BRCA-likeCGH tumors (adjusted hazard ratio 0.90, 95% CI: 0.53 to 1.54) (P = 0.004). Half of all
BRCA-likeCGH tumors were ER-positive.
Conclusions: Distinct aCGH patterns differentiated between HER2-negative patients with a markedly improved
outcome after adjuvant treatment with an intensified DNA-DSB-inducing regimen (BRCA-likeCGH patients) and
those without benefit (non-BRCA-likeCGH patients).* Correspondence: s.linn@nki.nl
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Adjuvant systemic treatment decisions for early breast
cancer are commonly based on results of large random-
ized clinical trials conducted in the general breast cancer
population. Such trials do not take into account the mo-
lecular heterogeneity present in breast cancer [1]. Con-
sequently, some treatment strategies that are highly
beneficial to a small percentage of the general breast
cancer population may have been discarded in the past.
An example of such a treatment strategy might be inten-
sified alkylating chemotherapy [2,3]. Here we investi-
gated whether a subgroup of breast cancer patients
exists that might derive substantial benefit from intensi-
fied platinum-based chemotherapy.
Maintenance of genomic integrity depends on homolo-
gous recombination, a conservative mechanism for error-
free repair of DNA double-strand breaks (DSBs). In the
absence of homologous recombination, error-prone DSB
repair mechanisms such as nonhomologous end joining
are invoked, leading to genomic instability [4-6]. This in-
stability is thought to predispose to familial breast cancer
in patients carrying germline mutations in BRCA1 or
BRCA2, genes involved in homologous recombination.
Absence of homologous recombination offers a potential
drug target for therapies that lead to DSBs during the
DNA replication phase, when homologous recombination
is the dominant DSB repair mechanism. Examples of these
therapies are bifunctional alkylating agents and platinum
compounds, which cause DNA crosslinks leading to DSBs
during DNA replication, and poly(ADP-ribose)polymerase
(PARP)-inhibitors [7,8], which inhibit repair of single-
strand DNA breaks also resulting in DSBs during
replication. Recent evidence indeed shows that BRCA1/2-
mutated breast cancers are particularly sensitive to such
agents [8-11]. This sensitivity is likely not restricted to
BRCA1/2-mutated breast cancers, as it is thought that up
to 30% of sporadic (germline BRCA wild-type) breast can-
cers have defects in homologous recombination repair, a
phenotype that is often referred to as ‘BRCAness’ [12]. In
order to identify sporadic breast cancers sensitive to DSB-
inducing agents, many studies have focused on triple-
negative (hormone receptor-negative and HER2-negative)
breast cancers (TNBCs), as these cluster with BRCA1-
mutated breast cancers within the basal-like molecular
subtype [13,14]. Consequently, multiple trials with DSB-
inducing agents have been performed in patients with
TNBC and indeed have shown good responses to these
agents, not only in BRCA1-mutation carriers [9,10]. How-
ever, in order to discern general chemosensitivity from
agent-specific sensitivity, a randomized controlled trial
(RCT) context is required, or, less ideal, a matched case-
control setup [15].
We have previously employed array comparative gen-
omic hybridization (aCGH) to assess the genomic profilesof BRCA1-mutated breast cancers [16]. It appeared that
some sporadic breast cancers had aCGH patterns that re-
sembled BRCA1-mutated breast cancers [17,18]. Further-
more, the BRCA1-like aCGH pattern was associated with
benefit from a high-dose (HD) DSB-inducing regimen,
and with a triple-negative (TN) phenotype [18].
BRCA2-mutated breast cancers show a similar distri-
bution across the breast cancer subtypes as sporadic
tumors (approximately 70% estrogen receptor (ER)- or
progesterone receptor (PR)-positive) [19], and ways to
select patients with sporadic ER-positive tumors sensi-
tive to DSB-inducing agents have been lacking thus far.
Recently, a BRCA2-like CGH pattern was defined and
found to be present in some sporadic breast cancers as
well [17]. In contrast to the BRCA1-like CGH pattern,
the BRCA2-like CGH pattern was frequently observed
in ER-positive tumors.
Given the association of the BRCA1-like CGH pattern
with benefit from HD DSB-inducing chemotherapy, we
hypothesized that a positive BRCA-likeCGH status (the
presence of a BRCA1-like and/or BRCA2-like CGH pat-
tern) might identify, besides ER-negative, also ER-positive
breast cancer patients who could benefit from DNA cross-
linking agents. To explore this, we studied tumor specimens
of breast cancer patients from a large RCT who had either
received adjuvant, conventional 5-fluorouracil-epirubicin-
cyclophosphamide (FE90C) chemotherapy followed by HD
cyclophosphamide-thiotepa-carboplatin (CTC), a DNA
cross-linking regimen, or conventional FE90C chemo-
therapy only [20]. We should note that this trial did not
show superiority of HD-CTC over FEC, although sub-
group analyses showed a better survival with HD-CTC
in patients with HER2-negative tumors [21].
To enrich for cases likely to derive benefit from HD-
CTC, we selected patients with HER2-negative tumors. By
employing the BRCA-likeCGH status, we identified a sub-
group of breast cancer patients with a remarkably good
outcome after adjuvant HD-CTC compared to conven-
tional FE90C chemotherapy, irrespective of hormone recep-
tor status. Vice versa, we identified the subgroup that did
not seem to derive any benefit from adjuvant HD-CTC.
Methods
Patients
Patients were part of a multicenter RCT performed in
the Netherlands (1993 to 1999) [20]. In this trial, 885
breast cancer patients with at least four tumor-positive
axillary lymph nodes but no distant metastases (stage III
disease) had been randomized to conventional FE90C
chemotherapy or the same therapy of which the last
course had been replaced by HD-CTC chemotherapy
with autologous stem cell support. Medical ethics com-
mittees of all participating centers approved the study
protocol and all patients gave consent for participating in
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were as follows (all in the Netherlands): The Netherlands
Cancer Institute, Amsterdam; Free University Medical Center,
Amsterdam; Academic Medical Center, Amsterdam; Leiden
University Medical Center, Leiden; University Medical Center
Groningen, Groningen; Maastricht University Medical
Center, Maastricht; University Medical Center Nijmegen,
Nijmegen; Erasmus Medical Center Cancer Institute,
Rotterdam; Medisch Spectrum Twente, Enschede; University
Medical Center Utrecht, Utrecht.
For this study, we randomly selected a group of 320
(out of 621) HER2-negative breast cancer patients. This
group was used previously to study the association of
the BRCA1-like CGH pattern with benefit from HD-
CTC [18]. Patients were included in the current study if
formalin-fixed paraffin-embedded (FFPE) primary tumor
tissue contained more than 60% tumor cells. Of these
320 patients we obtained aCGH profiles of 249 patients;
the flow of the study and reasons for dropout are depicted
in Figure 1. Patients selected for analyses did not differ in
patient characteristics or treatment from those not se-
lected for analyses (Table S7 in Additional file 1).
Treatment
Conventional chemotherapy consisted of five courses of
5-fluorouracil 500 mg/m2, epirubicin 90 mg/m2, cyclo-
phosphamide 500 mg/m2 (FE90C) given every three weeks
[20]. The HD-CTC arm consisted of four FE90C courses,
after which HD-CTC was administered (6,000 mg/m2
cyclophosphamide, 480 mg/m2 thiotepa and 1,600 mg/m2
carboplatin [20]. Patients in both treatment arms received
radiotherapy and tamoxifen as described earlier [20].
Array comparative genomic hybridization
aCGH patterns of 230 patients generated previously on
a 3.5 k Human BAC array National Center for Biotech-
nical Information (NCBI)'s Gene Expression Omnibus
platform number: GPL4560) platform were used in this
study [18]. Tumors of 19 patients could additionally be
analyzed (Figure 1). In short, genomic DNA was ex-
tracted from FFPE primary tumors [22]. For seven of
these 19 additional patients, only lymph node tissue con-
taining primary tumor tissue, removed at first diagnosis,
was available. Three of these 19 samples had DNA con-
centrations too low for direct aCGH analysis and were
amplified with the BioScore™ Screening and Amplifica-
tion Kit (42440, Enzo Life Sciences, Farmingdale, NY,
USA). Tumor and reference DNA was labeled according
to the manufacturer’s instructions (Kreatech Biotechnol-
ogy, Amsterdam, The Netherlands) and used for aCGH
on the same 3.5 k Human BAC array platform, as previ-
ously described [23]. Quality of each aCGH pattern was
determined using a profile quality and hybridization
quality score, as published previously [18].BRCA-likeCGH status
Each aCGH profile was classified as either BRCA1-like or
non-BRCA1-like and as either BRCA2-like or non-BRCA2-
like as previously published based on respectively the evalu-
ation of the BRCA1-like [18], and the BRCA2-like CGH
pattern [17].
The BRCA-likeCGH class contained tumors with a
BRCA1-like and/or a BRCA2-like CGH pattern; all other
tumors were assigned to the non-BRCA-likeCGH class.
The reproducibility of the BRCA-likeCGH status was
tested by hybridizing 21 tumor DNA samples in dupli-
cate. Two tumors in total switched classes from BRCA-
likeCGH score upon second hybridization (in the analysis
the first aCGH hybridization was used).
Histopathology
Hematoxylin and eosin slides were scored for tumor per-
centages by a breast cancer pathologist (JW). ER, PR, P53,
and HER2 status were determined by immunohistochem-
istry and scored as described previously [20,24].
Statistical analyses
Groups of interest were tested for differences using
Fisher’s exact tests and chi = square tests for trend.
Recurrence-free survival (RFS) was defined as the time
between randomization and appearance of local or re-
gional recurrence, metastases or death from any cause,
whichever came first [20]. Overall survival (OS) was
calculated from randomization to death from any cause,
or end of follow-up. Patients alive at last follow-up
were censored at that time. Median RFS and OS were
7.7 and 8.3 years, respectively, for all 249 patients. Sur-
vival curves were computed using the Kaplan-Meier
method and compared using log-rank tests; Cox regres-
sion was used to calculate hazard ratios (HR). To ensure a
direct correlation between aCGH pattern and treatment
received, only patients who completed their assigned
treatment were analyzed (per protocol analysis).
This study was designed according to the predictive
marker trial design ‘Indirect assessment: marker by treat-
ment interaction design, test of interaction’ (design 2) [25].
With this design the hypothesis can be tested whether the
treatment effect (that is HD-CTC versus FE90C) on sur-
vival in the presence of the marker (that is BRCA-likeCGH)
is significantly different from that in the absence of the
marker (that is non-BRCA-likeCGH) with a statistical test
for interaction.
Evidence for non-proportional hazards was found; all
multivariate Cox regression models were therefore strati-
fied for number of lymph nodes (4-9 vs. ≥10) and TN sta-
tus (ER <10% and PR <10% vs. other), which ensured
hazards were proportional.
All calculations were performed using the statistical
package SPSS 15.0 (for Windows) (SPSS Inc., Chicago, IL,
Figure 1 Flow diagram of patient selection in the study. Flow diagram depicting the number of patients and reasons for dropout (red boxes)
and the number of patients remaining after each adjustment step (grey boxes). Tumors of 249 patients could be evaluated for the presence of
the BRCA1-likeCGH and BRCA2-likeCGH pattern. The blue boxes at the bottom indicate the number of patients assigned to the BRCA1-likeCGH,
BRCA2-likeCGH and BRCA-likeCGH categories. aCGH, array comparative genomic hybridization.
Vollebergh et al. Breast Cancer Research 2014, 16:R47 Page 4 of 13
http://breast-cancer-research.com/content/16/3/R47USA). Figure S1 in Additional file 2 was generated using
the ggplot2 package in R version 2.12.1.
Results
Frequency of BRCA-likeCGH status and patient characteristics
aCGH profiles could be obtained from 249 tumors. Thirty
tumors were classified as BRCA1-like (BRCA1-likeCGH),
39 tumors as BRCA2-like (BRCA2-likeCGH) and 12 tu-
mors as both BRCA1- and BRCA2-likeCGH (Figure 1);
thereby assigning 81 patients to the BRCA-likeCGH class(81/249, 32%; Figure 1). Patients with BRCA-likeCGH
tumors were generally younger and their tumors were
more often ER-negative, PR-negative and poorly differ-
entiated compared to patients with non-BRCA-likeCGH
tumors (Table 1). BRCA1-likeCGH tumors were more
often ER-negative (36/42, 86%; Table S1 in Additional
file 1) than BRCA2-likeCGH tumors (16/51, 31%; Table
S2 in Additional file 1). Figure S1 in Additional file 2
summarizes grade, receptor and BRCA-likeCGH status
per patient.
Table 1 Patient characteristics by BRCA-likeCGH status
Variable Patients with non-BRCA-likeCGH tumors Patients with BRCA-likeCGH tumors P values
n % n %
Total 168 67.5 81 32.5
Treatment
FE90C chemotherapy 81 48.2 41 50.6 0.787
HD-CTC chemotherapy 87 51.8 40 49.4
Type of surgery
Breast-conserving therapy 33 19.6 18 22.2 0.620
Mastectomy 135 80.4 63 77.8
Age in categories
<40 years 34 20.2 27 33.3 0.032*
40 - 49 years 91 54.2 39 48.1
≥50 years 43 25.6 15 18.5
Tumor classification
T1 32 19.0 15 18.5 0.642*
T2 112 66.7 51 63.0
T3 23 13.7 14 17.3
Unknown 1 0.6 1 1.2
Number of positive lymph nodes
4-9 109 64.9 54 66.7 0.887
≥10 59 35.1 27 33.3
Histologic grade
I 51 30.4 4 4.9 <0.001*
II 70 41.7 23 28.4
III 42 25.0 50 61.7
Not determined 5 3.0 4 4.9
Estrogen receptor status
Negative (<10%) 25 14.9 40 49.4 <0.001
Positive (≥10%) 143 85.1 41 50.6
Progesterone receptor status
Negative (<10%) 50 29.8 51 63.0 <0.001
Positive (≥10%) 118 70.2 28 34.6
Unknown 0 0.0 2 2.5
Triple-negative status
Triple-negative 22 13.1 38 46.9 <0.001
ER or PR positive (>10%) 146 86.9 41 50.6
Unknown 0 0.0 2 2.5
P53 status
<10% 99 58.9 43 53.1 0.087*
10 - 50% 48 28.6 11 13.6
>50% 16 9.5 19 23.5
Unknown 5 3.0 8 9.9
P values: patients with unknown values were omitted. P values were calculated using the Fisher’s exact test, except for *chi-square test for trend. FE90C, 5-fluorouracil-
epirubicin-cyclophosphamide; HD-CTC, high-dose cyclophosphamide-thiotepa-carboplatin; ER, estrogen receptor; PR, progesterone receptor.
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within the patient subgroups (with either a BRCA- or
non-BRCA-likeCGH tumor; Table S3 in Additional file 1).
In univariate Cox regression analyses, large pathological
tumor size according to the tumor, node, metastasis
(TNM) classification, high number of positive lymph
nodes, poor Bloom-Richardson grade (BR grading sys-
tem), TN status, aCGH BRCA1-like pattern and conven-
tional FE90C treatment were significantly associated with
decreased OS (Table S4 in Additional file 1). All further
Cox regression analyses were therefore stratified for
triple negativity and number of positive lymph nodes,
and adjusted for pathological tumor size, BR grade,
aCGH BRCA-like status and treatment.
Although aCGH BRCA1-like pattern was an adverse
prognostic factor in univariate analysis (Table S4 in
Additional file 1), it lost its prognostic value in multi-
variate analysis (Table S5 in Additional file 1), since it
was highly associated with young age, TNBC, and poor
histological grade (Table S1 in Additional file 1). The
aCGH BRCA2-like pattern, however, was associated
with an adverse prognosis in multivariate analysis
(Table S5 in Additional file 1). One of the reasons that
this was obscured in univariate analysis is that the
BRCA1-likeCGH tumors ended up in the non- BRCA2-
likeCGH tumor group, thereby confounding the analysis.
This was corrected for in multivariate analysis (Table
S5 in Additional file 1).
Different treatment effects on survival between patients
with BRCA-likeCGH and non-BRCA-likeCGH tumors
Patients with a BRCA-likeCGH tumor had a significantly
better OS after HD-CTC compared with conventional
FE90C (adjusted HR 0.19, 95% CI: 0.08 to 0.48, Table 2,
Figure 2A), while there was no survival difference be-
tween treatment arms among patients with non-BRCA-
likeCGH tumors (adjusted HR 0.90, 95% CI: 0.53 to 1.54,
Table 2, Figure 2B). The effect of HD-CTC over conven-
tional FE90C chemotherapy was significantly different
between patients with BRCA-likeCGH tumors and non-
BRCA-likeCGH tumors (test for interaction P = 0.004,
Table 2). Similar results were obtained for RFS (Figure S2A
and S2B in Additional file 2, test for interaction P = 0.003),
and when BRCA1-likeCGH status and BRCA2-likeCGH sta-
tus were analyzed separately (Table S5 in Additional file 1,
Figure S3 in Additional file 1). The BRCA-likeCGH status
retained its predictive capacity within the following sub-
groups: TNBC patients (Table 2, Figures 2C and 2D),
ER-positive patients (Table 2, Figures 2E and 2F), pa-
tients younger than 45 years (Figure S4 in Additional
file 1, Table S6 in Additional file 1), and showed a
strong trend in patients with histological grade III tu-
mors only (Figure S4 in Additional file 1, Table S6 in
Additional file 1). We should note that subgroupanalyses should be interpreted with caution due to
small numbers in some subgroups.Effect of technical parameters on survival data
To determine the influence of the empirically chosen
thresholds of the aCGH quality (profile-quality score),
the minimal tumor percentage required for inclusion,
and the influence of the previously determined thresh-
olds defining the BRCA-likeCGH score (that is the
threshold of the BRCA1-likeCGH and BRCA2-likeCGH
patterns [17,18]), we varied the cutoffs around these
thresholds and evaluated the influence of these changes
on survival analyses. No substantial modification of the
HRs of treatment among patients with BRCA-likeCGH or
non-BRCA-likeCGH tumors (Figure 3), or of the tests for
interaction (all P values remained significant, Figure 3),
was observed.Discussion
In this study, we investigated whether we could identify a
subgroup of HER2-negative patients who would derive
substantial benefit from an intensified DNA DSB-inducing
regimen, cyclophosphamide-thiotepa-carboplatin, with au-
tologous stem cell support when compared to conven-
tional FE90C [20]. We hypothesized that the aCGH
patterns resembling BRCA1- or 2-mutated breast cancers
(BRCA-likeCGH status) would identify a subgroup of not
only TN, but also ER-positive, HER2-negative breast can-
cer patients with tumors exquisitely sensitive to DNA
DSB-inducing agents. Supporting evidence had come
from a case report describing a patient with BRCA2-mu-
tated metastatic breast cancer, who had been in continuous
complete remission for 11 years after HD DNA-cross-
linking chemotherapy with autologous stem cell support
[26], from our own metastatic series [18], from two early
PARP-inhibitor trials [8,11], and from preclinical work
[7,27,28]. Indeed, in the current study breast cancer pa-
tients with a BRCA-likeCGH tumor had a markedly better
OS after adjuvant HD-CTC than after conventional
chemotherapy; this selective benefit was not present in pa-
tients with a non-BRCA-likeCGH tumor, as confirmed by a
highly significant test for interaction. A substantial pro-
portion of HER2-negative breast cancer patients had a
BRCA-likeCGH tumor (81/249, 32%), which is close to the
predicted proportion of BRCAness in sporadic breast can-
cers (30%) [12]. Interestingly, the proportion of ER-
negative breast cancers among BRCA1-likeCGH and
BRCA2-likeCGH breast cancers was similar to that re-
ported for BRCA1-mutated and BRCA2-mutated breast
cancers, respectively [12,19].
Fifty-one percent (41/81) of the BRCA-likeCGH tumors
were ER-positive, making this the first study reporting
on a potential marker for sensitivity to intensified DSB-
Table 2 Multivariate Cox proportional-hazard analysis of the risk of death (OS) and BRCA-likeCGH status in all patients, patients with triple-negative tumors
only and patients with hormone receptor-positive tumors only













95% CI P value
pT-stage
pT1/pT2 65/200 1.00 17/44 1.00 48/156 1.00
pT3 22/37 1.93 1.16 - 3.21 0.012 10/13 2.46 1.03 - 5.88 0.043 12/24 1.71 0.88 - 3.32 0.114
Histologic grade
I/II 48/147 1.00 7/15 1.00 41/132 1.00
III 39/90 1.34 0.81 - 2.20 0.250 20/42 1.60 0.62 - 4.13 0.334 19/48 1.25 0.69 - 2.27 0.455
aCGH pattern*
Non-BRCA-likeCGH tumor 56/162 1.00 10/21 1.00 46/141 1.00
BRCA-likeCGH tumor 31/75 1.78 0.97 - 3.24 0.061 17/36 2.11 0.72 - 6.19 0.173 14/39 1.79 0.82 - 3.92 0.143
BRCA-likeCGH tumor*
FE90C chemotherapy 25/40 1.00 14/20 1.00 1.00 11/20 1.00
HD-CTC chemotherapy 6/35 0.19† 0.08 - 0.48 <0.001 3/16 0.19‡ 0.19‡ 0.05 – 0.66 3/19 0.19§ 0.05 - 0.71 0.013
Non-BRCA-likeCGH tumor* †Homogeneity: P = 0.004 ‡Homogeneity: P = 0.034 §Homogeneity: P = 0.048
FE90C chemotherapy 30/79 1.00 5/10 1.00 25/69 1.00
HD-CTC chemotherapy 26/83 0.89† 0.52 - 1.50 5/11 5/11 1.31‡ 0.37 - 4.64 0.676 21/72 0.82§ 0.46 - 1.46 0.493
Three separate multivariate Cox regression models were run in all patients†, in patients with TNBC‡, and in patients with HR-positive tumors§ (see top row) and an *interaction term with treatment; the first model was
stratified for number of lymph nodes (4-9 vs. ≥10) and triple-negative status (ER < 10% and PR < 10% vs. other) and based on 237 patients (12 patients contributing three events were excluded due to missing values
for at least one of the variables shown). For patients with TN tumors and with HR-pos tumors only, models were stratified for lymph node status only. The TN subgroup analyses were based on 57 patients (three
patients contributing two events were excluded due to missing values); for the HR-pos patients analyses were based on 180 patients (seven patients contributing zero events were excluded due to missing values). Test
of homogeneity of both treatment-specific hazard ratios based on an interaction term: P = 0.004 (†), P = 0.034 (‡) and, P = 0.048 (§) OS, overall survival; TN, triple-negative; HR-pos, hormone receptor-positive; pT stage,













Figure 2 (See legend on next page.)
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Figure 2 Association of the BRCA-likeCGH status with overall survival after HD-CTC and conventional chemotherapy. Kaplan-Meier survival
curves for OS were generated separately for all HER2-negative breast cancer patients with BRCA-likeCGH (A) and with non-BRCA-likeCGH (B) tumors; for
the subgroup of TNBC patients with BRCA-likeCGH (C) and with non-BRCA-likeCGH (D) tumors; and for the subgroup of hormone receptor-positive,
HER2-negative breast cancer patients with BRCA-likeCGH (E) and with non-BRCA-likeCGH tumors (F); who had been randomly assigned between
HD-PB chemotherapy and conventional chemotherapy. FE90C, 5-fluorouracil, epirubicin, cyclophosphamide; HD-CTC, high-dose cyclophosphamide-
thiotepa-carboplatin; HD-PB, high-dose platinum-based; HR-pos, hormone receptor-positive; OS, overall survival; TNBC, triple-negative breast cancer.
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Although there are indications that BRCA2-mutated
breast cancers and BRCA2-likeCGH tumors are slightly
more sensitive to standard chemotherapy than breast can-
cers not having these features [17,29,30], here we have
shown that patients with BRCA2-likeCGH tumors, just like
patients with BRCA1-likeCGH tumors, derive substantial
more benefit from intensified, DNA DSB-inducing agents
(CTC) than from conventional FE90C. Unfortunately, we
could not determine whether a lower, non-myeloablative
dose of CTC would also have resulted in a similarly im-
proved outcome. This is important, since high-dose mye-
loablative chemotherapy has been abandoned in breast
cancer treatment [3,31,32], although a small survival
advantage has been reported for HER2-negative breastFigure 3 Sensitivity analyses of the BRCA-likeCGH status. We varied the
(that is the threshold of the BRCA1-likeCGH and BRCA2-likeCGH patterns (1
(profile-quality status) and the tumor percentage, and evaluated the influ
BRCA1- and BRCA2-likeCGH patterns, which define the BRCA-likeCGH status
respectively (13, 14)); (B) similarly, thresholds were decreased by 0.1; (C) T
to 0.95 (14)), resulting in a subgroup of 225 patients; (D) The threshold o
subgroup of 198 patients. All analyses were stratified for number of lymp
and PR <10% vs. other) and adjusted for pathologic tumor size (T1 vs. T2
array comparative genomic hybridization; ER, estrogen receptor; FE90C, 5-fluor
cyclophosphamide-thiotepa-carboplatin; PR progesterone receptor.cancer in a recent meta-analysis [33]. In addition, it could
also be that patients with BRCA-like tumors benefitted
particularly from platinum rather than from the high-dose
therapy. We cannot differentiate between these options
due to the design of the original RCT. Another limitation
of this study is that patients were not treated by a taxane,
which is nowadays the standard of care for high-risk
breast cancer. Finally, the randomized trial only included
high-risk patients, younger than 55 years, with at least
four tumor-positive axillary lymph nodes (stage III dis-
ease). Further studies are in progress to determine if these
results are also applicable to other stages of breast cancer
(NCT01057069 and NCT01646034).
There is evidence of a dose-response relationship for
cyclophosphamide within a subgroup of breast cancers
[34]. In the neoadjuvant setting, cT3-4 breast cancerpreviously determined thresholds defining the BRCA-likeCGH status
3, 14)) and the empirically chosen thresholds of the aCGH quality
ence on results for overall survival. (A) The thresholds of the
, were increased by 0.1 (from 0.63 to 0.73 and from 0.5 to 0.6,
he threshold determining aCGH quality was increased (from 0.85
f tumor percentage was increased from 60% to 70% resulting in a
h nodes (4-9 vs. ≥10) and double-negative ER/PR status (ER <10%
vs. T3), histologic grade (I vs. II vs. III) and BRCA-likeCGH status. aCGH,
ouracil, epirubicin, cyclophosphamide; HD-CTC, high-dose
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http://breast-cancer-research.com/content/16/3/R47patients with a TP53-mutation had a higher likelihood of
pathological complete remission (pCR) and an 80% six-
years RFS after intensified cyclophosphamide-based
chemotherapy, but only a 50% six-year RFS after FEC-
docetaxel (FEC-D) [34,35]. The TP53 mutations were
determined using a yeast-based screen for functional
TP53 mutations [36]. Interestingly, these specific types
of TP53 mutations have been found in high frequencies
in BRCA1-mutated breast cancers [37] and could pos-
sibly function as an alternative marker for sensitivity to
DNA cross-linking agents. In line with this reasoning,
protein-truncating nonsense or frameshift TP53 muta-
tions were also found to predict good response (Miller-
Payne score 3,4,5) to neoadjuvant cisplatin in cT2,
TNBC patients [10]. At present the optimal intensified
cyclophosphamide dose is unclear. In the B-25 trial
breast cancer patients under 50 years of age with four to
nine positive axillary lymph nodes benefitted significantly
more from highly intensified (4*2,400 mg/m2 q 3 weeks)
than from moderately intensified cyclophosphamide-
based chemotherapy (4*1,200 mg/m2 q 3 weeks) [2];
similarly, in the CONSORT study (breast cancer pa-
tients with ≥4 axillary involved lymph nodes), intense
dose-dense sequential epirubicin, paclitaxel and cyclo-
phosphamide (3*2,500 mg/m2 q 2 weeks) significantly
improved survival outcome compared with conven-
tional chemotherapy [38]. Of course, in these two latter
studies, no stratification based on a BRCAness marker
was made, which might have resulted in a much more
pronounced benefit in the BRCAness group.
The current study had been designed to test the hypoth-
esis that breast cancers with HRD would derive substan-
tially more benefit from intensified DNA DSB-inducing
agents than tumors without HRD. We assumed that the
BRCA-likeCGH status could be used as a proxy for breast
cancers with HRD. Circumstantial evidence for this was
derived from preclinical studies [4-8,12,39-43]. The pres-
ence of HRD is, however, not easy to establish in clinical
samples since a gold standard for HRD does not exist.
Therefore, we can only conclude that the BRCA-likeCGH
status can be used to identify patients who derive substan-
tial benefit from intensified DNA DSB-inducing agents.
Whether the BRCA-likeCGH status can also be used to se-
lect patients who will derive substantial benefit from
PARP-inhibitors is the subject of further studies.
As known, the performance of predictive biomarkers
can only be studied in two comparable groups of pa-
tients where only one group has received the treatment
of interest, thereby dissecting general chemosensitivity
and/or prognosis from selective sensitivity to a particular
treatment strategy [15,43,44]. The strength of the
current study is that BRCA-likeCGH status has been
tested in the context of a RCT with long-term follow-up.
The BRCA-likeCGH status is probably not the only wayto identify tumors that are sensitive to DNA DSB-
inducing agents. Several potential predictive markers
have been described in nonrandomized studies, such as
RAD51 staining [45], gene expression profiling [46],
telomere aberrations [47], BRCA1-promoter methyla-
tion, and BRCA1 gene expression measurements [10].
To assess the play of chance, sensitivity analyses were
performed showing that the results were robust with re-
gard to the choice of several technical parameters. The
association between HD-CTC benefit and the BRCA-
likeCGH status remained significant with relatively few
patients switching classes. Multivariate models, stratified
for lymph node status and TNBC subtype, were run to
assure that the observed differential treatment effects ac-
cording to BRCA-likeCGH status were independent of
histological grade and tumor size.
A technical restriction of this study was the use of an
aCGH platform with a lower resolution than currently
used platforms. The reason is that we had to employ the
same platform for validation as we had used to build the
classifiers. Of note, the low resolution regions employed
in the BRCA-likeCGH classifier will, of course, not dis-
appear when a higher resolution platform is employed.
Clearly, it is not the platform, but rather the chromo-
somal regions that are important and our findings
should be applicable on data generated by any technol-
ogy that identifies DNA gains and losses. Finally, an ad-
vantage of the aCGH assay is that it requires limited
amounts of DNA isolated from FFPE tissue.
In conclusion, we showed in a representative sample of
249 HER2-negative patients from a RCT that a BRCA-
likeCGH classification was able to identify both ER-positive
and TNBC patients who derived a marked benefit of inten-
sified DNA cross-linking chemotherapy. Patients with
BRCA-likeCGH tumors had about a five times lower risk of
death after HD-CTC compared to FE90C chemotherapy,
while no significant benefit was observed among patients
with non-BRCA-likeCGH tumors. This finding strongly sug-
gests the existence of breast cancer subtypes, defined by
distinct CGH patterns that have a markedly improved
outcome after treatment with an intensified DNA-cross-
linking regimen and may explain why high-dose chemo-
therapy trials carried out in the general breast cancer
population have remained negative in the past. This study
should be considered as a biomarker study with an II-B
level of evidence [15], since it tested the marker in a retro-
spective series. Therefore, before these results can be intro-
duced into daily clinical practice, they should be validated
in other controlled studies in which intensified alkylating
regimens and/or PARP-inhibitors have been employed.
Conclusions
aCGH patterns could differentiate between HER2-
negative patients with a markedly improved outcome
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inducing regimen (BRCA-likeCGH patients) and those
without benefit (non-BRCA-likeCGH patients).Additional files
Additional file 1: Table S1. Patient characteristics by BRCA1-likeCGH
status. Table S2. Patient characteristics by BRCA2-likeCGH status. Table S3.
Patient characteristics by treatment arm and BRCA-likeCGH status. Table S4.
Univariate Cox proportional hazard regression analysis of the risk of
death (OS) after randomization. Table S5. Multivariate Cox proportional
hazard analysis of the risk of death (OS) for patients with BRCA1-likeCGH
tumors, or BRCA2-likeCGH tumors compared to patients with non-BRCA-
likeCGH tumors. Table S6. Multivariate Cox proportional hazard analysis
of the risk of death (OS) and BRCA-likeCGH status in patients with grade III
tumors only and in patients younger than or equal to 45 years only
Table S7. Distribution of clinicopathological variables between randomly
selected HER2-negative patients included in this study and HER2-negative
patients not in the current analysis (all completed their assigned treatment).
Additional file 2: Figure S1. Overview of histological patient
characteristics and aCGH classification per patient. Figure S2. Association
of the BRCA-like CGH status with recurrence-free survival after HD-CTC
and conventional FE90C chemotherapy. Figure S3. Association of the
BRCA1-like CGH, the BRCA2-like CGH and the non-BRCA-like CGH status
with overall survival after HD-CTC and conventional FE90C chemotherapy.
Figure S4. Association of the BRCA-like CGH and the non-BRCA-like
CGH status with overall survival after HD-CTC and conventional FE90C
chemotherapy in patients with grade III tumors and in patients younger
than 45 years.Abbreviations
aCGH: array comparative genomic hybridization; BR: Bloom-Richardson grading
system; CTC: cyclophosphamide-thiotepa-carboplatin; DSB: double-strand break;
ER: estrogen receptor; FE90C: 5-fluorouracil-epirubicin-cyclophosphamide;
FFPE: formalin-fixed paraffin-embedded; HD: high-dose; HRD: homologous
recombination deficiency; OS: overall survival; PARP: poly(ADP-ribose)
polymerase; pCR: pathological complete remission; PR: progesterone receptor;
RCT: randomized controlled trial; RFS: recurrence-free survival; TN: triple
negative; TNBC: triple negative breast cancer.
Competing interests
S.C. Linn, M.A. Vollebergh and P.M. Nederlof are named inventors on a
patent application for the aCGH BRCA1-likeCGH classifier and additionally with
E.H. Lips as a contributor on a patent application for the aCGH BRCA2-likeCGH
classifier used in this study. All other authors of this manuscript declare they
have no financial and/or personal relationships with other people and/or
organizations that could influence or bias their work.
Authors’ contributions
SCL, LFAW, MH and SR were responsible for the study design. MAV and EHL
coordinated the study. PMN, LFAW and JJ developed the research methods
used. MAV, EHL, EGEdV and HvT took part in data collection. JW and MvdV
performed all histopathological analyses. MAV and EHL carried out all
experiments. MAV, EHL, MH and HvT performed the data analysis. MAV, EHL,
SCL, PMN, LFAW, JJ, HvT, and MH took part in data interpretation. MAV, EHL,
PMN, LFAW, JW, MvdV, EGEdV, HvT, JJ, MH, SR, SCL contributed to the
revising or critical drafting of the manuscript. MAV, EHL, PMN, LFAW, JW,
MvdV, EGEdV, HvT, JJ, MH, SR, SCL approved the final revised version of the
manuscript. All authors, external and internal, had full access to all of the
data (including statistical reports and tables) in the study.
Acknowledgments
We thank the The Netherlands Cancer Institute (NKI-AVL) central microarray
facility; Judy Jacobse and Simon Joosse for technical assistance; and Philip
Schouten for his art work. No medical writers were involved in writing this
manuscript.Funding
This work was supported by the Dutch Cancer Society, A Sister’s Hope/Pink
Ribbon and Center for Translational Molecular Medicine (CTMM) (project
Breast CARE grant 030-104). This study’s funders had no role in study design;
in the collection, analysis, and interpretation of data; in the writing of the
report; and in the decision to submit the manuscript for publication. The
researchers were all independent from these funders.
Author details
1Department of Molecular Pathology, the Netherlands Cancer Institute -
Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam,
The Netherlands. 2Department of Molecular Carcinogenesis, the Netherlands
Cancer Institute -Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066
CX Amsterdam, The Netherlands. 3Department of Pathology, the Netherlands
Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX
Amsterdam, The Netherlands. 4Department of Biometrics, the Netherlands
Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX
Amsterdam, The Netherlands. 5Department of Epidemiology and Biostatistics,
the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital,
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. 6Department of Medical
Oncology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital,
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. 7Faculty of Electrical
Engineering, Mathematics and Computer Science, Delft University of
Technology, Stevinweg 1, 2628 CN Delft, The Netherlands. 8Department of
Pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam,
The Netherlands. 9Department of Medical Oncology, University Medical
Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
10Department of Pathology, University Medical Center Utrecht,
Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Received: 8 October 2013 Accepted: 2 May 2014
Published: 15 May 2014
References
1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of
chemotherapy and hormonal therapy for early breast cancer on
recurrence and 15-year survival: an overview of the randomised trials.
Lancet 2005, 365:1687–1717.
2. Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L,
Henry PH, Romond EH, Lanier KS, Davila E, Kardinal CG, Laufman L, Pierce
HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic M, Tan-Chiu
E, Tian W, Wolmark N: Further evaluation of intensified and increased
total dose of cyclophosphamide for the treatment of primary breast
cancer: findings from National Surgical Adjuvant Breast and Bowel
Project B-25. J Clin Oncol 1999, 17:3374–3388.
3. Nieto Y, Shpall EJ: High-dose chemotherapy for high-risk primary and
metastatic breast cancer: is another look warranted? Curr Opin Oncol
2009, 21:150–157.
4. Karran P: DNA double strand break repair in mammalian cells. Curr Opin
Genet Dev 2000, 10:144–150.
5. Khanna KK, Jackson SP: DNA double-strand breaks: signaling, repair and
the cancer connection. Nat Genet 2001, 27:247–254.
6. van Gent DC, Hoeijmakers JH, Kanaar R: Chromosomal stability and the
DNA double-stranded break connection. Nat Rev Genet 2001, 2:196–206.
7. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S,
Meuth M, Curtin NJ, Helleday T: Specific killing of BRCA2-deficient tu-
mours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005,
434:913–917.
8. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P,
Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB,
Schellens JH, de Bono JS: Inhibition of poly(ADP-ribose) polymerase in
tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123–134.
9. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G,
Rocha C, Ossovskaya V, Sherman B, Bradley C: Efficacy of BSI-201, a poly
(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with
gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative
breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol
(Meeting Abstracts) 2009, 27:3.
10. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong
CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De
Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP,
Vollebergh et al. Breast Cancer Research 2014, 16:R47 Page 12 of 13
http://breast-cancer-research.com/content/16/3/R47Garber JE: Efficacy of neoadjuvant cisplatin in triple-negative breast
cancer. J Clin Oncol 2010, 28:1145–1153.
11. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN,
Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl
H, Wickens M, Carmichael J: Oral poly(ADP-ribose) polymerase inhibitor
olaparib in patients with BRCA1 or BRCA2 mutations and advanced
breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
12. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers.
Nat Rev Cancer 2004, 4:814–819.
13. V’ ant Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL,
van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM,
Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling
predicts clinical outcome of breast cancer. Nature 2002, 415:530–536.
14. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen
H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO,
Borresen-Dale AL, Botstein D: Repeated observation of breast tumor
subtypes in independent gene expression data sets. Proc Natl Acad Sci
U S A 2003, 100:8418–8423.
15. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of
prognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101:1446–1452.
16. Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N,
Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM:
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast car-
cinomas with array-CGH. Breast Cancer Res Treat 2009, 116:479–489.
17. Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MT, van de
Vijver MJ, Wesseling J, Nederlof PM, Rodenhuis S: Indicators of homologous
recombination deficiency in breast cancer and association with response
to neoadjuvant chemotherapy. Ann Oncol 2011, 22:870–876.
18. Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Schmidt MK, van Beers
EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EG, Schrama JG,
Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M,
Rodenhuis S, Linn SC: An aCGH classifier derived from BRCA1-mutated
breast cancer and benefit of high-dose platinum-based chemotherapy in
HER2-negative breast cancer patients. Ann Oncol 2011, 22:1561–1570.
19. Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog
L, Easton DF: The pathology of familial breast cancer: predictive value of
immunohistochemical markers estrogen receptor, progesterone
receptor, HER-2, and p53 in patients with mutations in BRCA1 and
BRCA2. J Clin Oncol 2002, 20:2310–2318.
20. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest
EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG:
High-dose chemotherapy with hematopoietic stem-cell rescue for
high-risk breast cancer. N Engl J Med 2003, 349:7–16.
21. Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE,
van der Wall E, Hupperets P, van Tinteren H, Peterse JL, van de Vijver MJ, de
Vries EG: Efficacy of high-dose alkylating chemotherapy in HER2/
neu-negative breast cancer. Ann Oncol 2006, 17:588–596.
22. van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FB, Verhoef S,
Nederlof PM: A multiplex PCR predictor for aCGH success of FFPE
samples. Br J Cancer 2006, 94:333–337.
23. Joosse SA, van Beers EH, Nederlof PM: Automated array-CGH optimized
for archival formalin-fixed, paraffin-embedded tumor material. BMC
Cancer 2007, 7:43.
24. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O,
Nusse R: Neu-protein overexpression in breast cancer. Association with
comedo-type ductal carcinoma in situ and limited prognostic value in
stage II breast cancer. N Engl J Med 1988, 319:1239–1245.
25. Sargent DJ, Conley BA, Allegra C, Collette L: Clinical trial designs for
predictive marker validation in cancer treatment trials. J Clin Oncol 2005,
23:2020–2027.
26. Huang F, Kushner YB, Langleben A, Foulkes WD: Eleven years disease-free:
role of chemotherapy in metastatic BRCA2-related breast cancer. Nat Rev
Clin Oncol 2009, 6:488–492.
27. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB,
Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith
GC, Ashworth A: Targeting the DNA repair defect in BRCA mutant cells as
a therapeutic strategy. Nature 2005, 434:917–921.
28. Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, Edser
P, Adams DJ, Wade-Martins R, Bouwman P, Jonkers J: A high-throughput
pharmaceutical screen identifies compounds with specific toxicity
against BRCA2-deficient tumors. Clin Cancer Res 2010, 16:99–108.29. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB,
Bartels CC, Tilanus-Linthorst MM, Blom J, Huijskens E, Jager A, van den
Ouweland A, van Geel B, Hooning MJ, Brekelmans CT, Klijn JG: Sensitivity to
first-line chemotherapy for metastatic breast cancer in BRCA1 and
BRCA2 mutation carriers. J Clin Oncol 2009, 27:3764–3771.
30. Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH,
Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW, Seynaeve C: The
efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1
and BRCA2 mutation carriers. Cancer 2012, 118:899–907.
31. Rodenhuis S: The status of high-dose chemotherapy in breast cancer.
Oncologist 2000, 5:369–375.
32. Farquhar CM, Marjoribanks J, Lethaby A, Basser R: High dose chemotherapy
for poor prognosis breast cancer: systematic review and meta-analysis.
Cancer Treat Rev 2007, 33:325–337.
33. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP,
Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL,
Zander AR, Coombes RC, Roche H, Tokuda Y, de Vries EG, Hortobagyi GN,
Crown JP, Pedrazzoli P, Bregni M, Demirer T: High-dose chemotherapy
with autologous stem-cell support as adjuvant therapy in breast cancer:
overview of 15 randomized trials. J Clin Oncol 2011, 29:3214–3223.
34. Lehmann-Che J, Andre F, Desmedt C, Mazouni C, Giacchetti S, Turpin E,
Espie M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF,
Pusztai L, de The H: Cyclophosphamide dose intensification may
circumvent anthracycline resistance of p53 mutant breast cancers.
Oncologist 2010, 15:246–252.
35. Giacchetti S, Lehmann-Che J, De Roquancourt A, Cuvier C, Turpin E, Marty
M, Bertheau P, de The H, Espie M: Complete pathological response
according to hormonal status, C-ErbB2 and P53 in two neoadjuvant
treatments in locally advanced breast cancers. Cancer Res 2009,
69:Abstract nr 5107.
36. Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, Feugeas JP, Plassa
LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y,
Marty M, Misset JL, Janin A, de The H: Exquisite sensitivity of TP53 mutant
and basal breast cancers to a dose-dense epirubicin-cyclophosphamide
regimen. PLoS Med 2007, 4:e90.
37. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J:
High incidence of protein-truncating TP53 mutations in BRCA1-related
breast cancer. Cancer Res 2009, 69:3625–3633.
38. Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn
W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G,
Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M: Intense
dose-dense sequential chemotherapy with epirubicin, paclitaxel, and
cyclophosphamide compared with conventionally scheduled
chemotherapy in high-risk primary breast cancer: mature results of
an AGO phase III study. J Clin Oncol 2010, 28:2874–2880.
39. Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van
de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, Schouten JP,
Jonkers J, Borst P: Selective induction of chemotherapy resistance of
mammary tumors in a conditional mouse model for hereditary breast
cancer. Proc Natl Acad Sci U S A 2007, 104:12117–12122.
40. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander
SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A,
O'Connor MJ, Martin NM, Borst P, Jonkers J: High sensitivity of BRCA1-
deficient mammary tumors to the PARP inhibitor AZD2281 alone and in
combination with platinum drugs. Proc Natl Acad Sci U S A 2008,
105:17079–17084.
41. Holstege H, Van BE, Velds A, Liu X, Joosse SA, Klarenbeek S, Schut E,
Kerkhoven R, Klijn CN, Wessels LF, Nederlof PM, Jonkers J: Cross-species
comparison of aCGH data from mouse and human B. BMC Cancer 2010,
10:455.
42. Rottenberg S, Vollebergh MA, de HB, de RJ, Schouten PC, Kersbergen A,
Zander SA, Pajic M, Jaspers JE, Jonkers M, Loden M, Sol W, van der BE,
Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers
J, Borst P: Impact of intertumoral heterogeneity on predicting
chemotherapy response of BRCA1-deficient mammary tumors. Cancer
Res 2012, 72:2350–2361.
43. Vollebergh MA, Jonkers J, Linn SC: Genomic instability in breast and
ovarian cancers: translation into clinical predictive biomarkers. Cell Mol
Life Sci 2012, 69:223–245.
44. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker
GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ: Tumor
Vollebergh et al. Breast Cancer Research 2014, 16:R47 Page 13 of 13
http://breast-cancer-research.com/content/16/3/R47marker utility grading system: a framework to evaluate clinical utility of
tumor markers. J Natl Cancer Inst 1996, 88:1456–1466.
45. Asakawa H, Koizumi H, Koike A, Takahashi M, Wu W, Iwase H, Fukuda M,
Ohta T: Prediction of breast cancer sensitivity to neoadjuvant
chemotherapy based on status of DNA damage repair proteins. Breast
Cancer Res 2010, 12:R17.
46. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E,
Francoeur N, Levine DA, Cannistra SA: Gene expression profile of
BRCAness that correlates with responsiveness to chemotherapy and
with outcome in patients with epithelial ovarian cancer. J Clin Oncol
2010, 28:3555–3561.
47. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y,
Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi
Z, Richardson AL: Telomeric allelic imbalance indicates defective DNA
repair and sensitivity to DNA-damaging agents. Cancer Discov 2012,
2:366–375.
doi:10.1186/bcr3655
Cite this article as: Vollebergh et al.: Genomic patterns resembling
BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified
carboplatin-based chemotherapy. Breast Cancer Research 2014 16:R47.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
